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Short title: 
Nicotinamide inhibits human hair follicle growth 
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To the Editor, 
The effective inhibition of unwanted human hair growth by safe and well-tolerated topical 
agents remains a major drawback of clinical and cosmetic dermatological treatments (Somani 
and Turvy 2014). One key challenge is to promote hair follicle (HF) regression (catagen) 
with negligible skin toxicity or irritation (S1). Pilot evidence suggests that nicotinamide, an 
amide form of vitamin B3 (Forbat et al. 2017), may be capable of doing this. That 
nicotinamide is used as a cosmetic and a dermatotherapeutic agent (Chen et al. 2016; Forbat 
et al. 2017; Niren 2006) (Supplementary Text ST1a) (Niren 2006; Walocko et al. 2017; S2) 
makes it an attractive candidate for hair growth inhibition. Therefore, we have investigated 
the hypothesis that nicotinamide may be an effective hair growth-inhibitor.  
Micro-dissected human scalp HFs were obtained with institutional approval and written 
informed patient consent (Langan et al. 2015). These were cultured in the presence of 200 
µM or 10 mM (Supplementary text ST1b) nicotinamide for 6 days, and key human hair 
biology read-out parameters were assessed (Kloepper et al. 2010; Ramot et al. 2014). 
HFs treated with nicotinamide (10 mM) showed significantly decreased hair shaft production 
(Figure 1a) and entered catagen more rapidly than vehicle control HFs (Figure 1b, example 
staging Figure S1). This was confirmed by double-immunohistomorphometry (Ki-
67/TUNEL), which showed significantly decreased hair matrix keratinocyte proliferation (Ki-
67) below Auber’s line (AL), increased apoptosis (TUNEL) within the hair matrix in anagen-
phase HFs, showing a hair cycle independent effect of nicotinamide, (Figure 1c, d), with no 
effect on HF melanin content (Figure S2, Supplementary text ST1).  
As nicotinamide added to culture medium imitates “systemic” application, we next asked if 
topical application to organ cultured human scalp skin (Supplementary Text ST2) (Lu et al. 
2007) also inhibited human hair growth. Results showed that HFs treated with topical 
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nicotinamide (10 mM) entered and progressed through catagen faster than vehicle treated 
skin (day 3 and 6) (Figure 1e, Figure S1) with a corresponding, significant decrease in 
proliferation (Ki-67) (Figure 1f, g), mirroring HF organ culture experiments.  
 
To exclude potential leaching of topical formulations into the medium we refined this assay 
by suspending the skin within an air-permeable membrane (see Supplementary Text ST2).  In 
addition, we tested a modified topical nicotinamide formulation (i.e. 1% , matching 10 mM 
nicotinamide [Figs. 1a-g]) or 4% (common cosmetic concentrations (Navarrete-Solís et al. 
2011, S2)), using a hydrosome-based vehicle, a clinical grade vehicle that promotes skin 
penetration (S3). 
 
In this assay, the nicotinamide-hydrosome preparation (1% and 4%) significantly increased 
the number of catagen-like HFs (Figure 2a, Figure S1) (Oh et al. 2016). In line with this, the 
percentage of apoptotic (TUNEL+) HF matrix keratinocytes increased (Figure 2b, d) while 
the percentage of proliferating (Ki-67+) HF keratinocytes was significantly decreased (Figure 
2c, d), with no effect on melanocyte proliferation (Figure S2). Moreover, topical 
nicotinamide (4%) also decreased the intrafollicular protein immunoreactivity for keratin 85, 
a surrogate marker for hair shaft production (S4) (Figure 2e, f), demonstrating hair growth 
inhibition was maintained using this vehicle. 
 
As epilation devices and depilatory creams typically induce skin irritation and/or pruritus 
(S5), we examined potential adverse side-effects of nicotinamide by investigating mast cell 
(MC) granulation status, a sign of irritation, in the interfollicular dermis and HF connective 
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tissue sheath (CTS) using immunohistomorphometry of mast cell-tryptase (MCT). Contrary 
to previous reports showing nicotinamide reduced MC degranulation (Navarrete-Solís et al. 
2011; Niren 2006), 1% nicotinamide added to the HF medium significantly increased MC 
degranulation (Figure S3a, b) in the HF connective tissue sheath.  
Comparing this to skin organ culture, no significant change in MC degranulation resulted 
from 1% nicotinamide-hydrosome applied topically, though a significant increase by 4% 
nicotinamide-hydrosome was detected (Figure 2g, h). Comparatively, nicotinamide-PEG6000 
induced degranulation at a concentration of 1% (Figure 2i) suggesting a hydrosome vehicle 
may have some ability to reduce degranulation when used in combination with lower 
concentrations of nicotinamide (Discussion point Supplementary ST1f).  
 
To further probe skin inflammation by topical nicotinamide, the number of CD68+ dermal 
macrophages was also investigated finding a significant decrease by 4% nicotinamide-
hydrosome with a trend towards decreased numbers by 1% (Figure S4c, g). This suggests that 
nicotinamide does not induce lymphocytic inflammation but may induce itch and/or 
neurogenic inflammation. For this reason, a method for reducing MC degranulation whilst 
maintaining hair growth inhibition was examined. 
 
For this purpose, palmitoylethanolamide (PEA, 30µM), an anti-pruritic endocannabinoid 
used in clinical dermatology, was applied to our nicotinamide/PEG6000 formulation 
(Supplementary text ST1b,c) and applied topically to ex vivo scalp sin to reduce MC 
degranulation (Parrella et al. 2016, S7).  
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The addition of PEA significantly reduced nicotinamide-induced dermal MC degranulation 
ex vivo (Figure 2i) without altering the hair growth inhibitory effect (Figure 2j). This supports 
the addition of PEA to future nicotinamide products to reduce MC degranulation-associated 
itch/inflammation while maintaining hair growth-inhibition (Supplementary text ST1d). 
 
To examine the potential for topical nicotinamide-hydrosome (1% and 4%) formulations to 
cause additional epidermal side-effects which would render them unsuitable as a hair growth-
inhibitory products (Cerchia and Lavecchia 2017), epidermal proliferation, apoptosis and 
pigmentation was assessed by quantitative immunohistomorphometry (Ki-
67/TUNEL/Masson-Fontana). Neither 1% or 4% topical nicotinamide-hydrosome 
formulation significantly altered epidermal proliferation, apoptosis or pigmentation (Figure 
S4A,B, D-F) (supplementary text ST1e for discussion point).  
 
Taken together these data present clear evidence that nicotinamide can effectively inhibit 
human hair growth and promote catagen in our clinically relevant models. That this occurred 
at commercially/clinically relevant concentrations without negatively affecting epidermal 
vitality or pigmentation makes nicotinamide an excellent cosmeceutical hair growth inhibitor 
for subsequent clinical testing. Data also suggest that hydrosomes provide a suitable vehicle 
and that PEA addition may reduce any potential skin irritation/itch that might be seen after 
repetitive application in vivo. 
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Figure Legends 
Figure 1: Nicotinamide inhibits hair growth and induces catagen.  
Human hair follicles (HFs) were cultured for 6 days with nicotinamide 
(200µM/10mM/vehicle) finding that (a) hair shaft elongation was decreased by 10mM 
nicotinamide with a (b) corresponding increase in catagen HFs (c,d),  a significant decrease in 
Ki-67+ cells below Auber’s line (AL) and an increase in TUNEL+ cells in the matrix 
compared to vehicle.  When nicotinamide (10mM) was topically applied to human scalp skin, 
(e) a higher proportion of catagen HFs were detected (day 3) with more mid/late catagen at 
day 6 (f,g) and a matching decrease in Ki-67+ cells below AL compared to vehicle in anagen 
HFs. DP, dermal papilla; Data= mean; ± SEM; one-way ANOVA with Bonferroni’s post-test. 
*P<0.05, **P<0.01, and ***P<0.001. Scale bar=50 µm. 
 
 
Figure 2: Topical nicotinamide can reduce hair growth and prevent mast cell 
degranulation with the addition of PEA. 
Using commercial formulations and a hydrosome vehicle showed that (a) both 1% and 4% 
nicotinamide induced catagen, (b) significantly increased TUNEL+ cells in the hair matrix 
and (c-d) significantly decreased Ki67+ below Auber’s line. (e,f) As a surrogate marker for 
hair growth, Keratin 85 (K85) immunofluorescence was by nicotinamide (significant at 4%). 
(g) Notably topical nicotinamide (4%) did significantly induce mast cell degranulation in the 
interfollicular dermis which could be reduced by 30µM PEA (h, i) while maintaining hair 
growth inhibition (j). Data=mean± SEM; one-way ANOVA with bonferroni’s post-test or 
student’s unpaired t-test; w *P<0.05, **P<0.01, and ***P<0.001. Scale bar = 50 µm. 
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